Patent Grant
12162914
The field of the invention pertains to chemically or enzymatically modified preparations of synthetic secretoglobins that have altered or enhanced properties compared to the unmodified versions. More specifically, modification of recombinant human secretoglobin proteins using reactive oxygen species (ROS), reactive nitrogen species (RNS), enzyme catalyzed modification such as myeloperoxidase plus hydrogen peroxide, or transglutaminase catalyzed modification. The invention further pertains to characterization of new isoforms of modified secretoglobins, optimized processes for modifying secretoglobins, and isolation of secretoglobin isoforms. The term “isoform” herein refers to a secretoglobin or CC10 monomer, dimer, or other multimer complex that contains intact monomers of at least 60 amino acids in length that contain one or more chemically modified amino acids. The invention further pertains to alteration of the biological activity, change in the structural conformation, or biochemical properties of a secretoglobin by chemical or enzymatic modification of one or more of its amino acids. The invention further pertains to enhancing the anti-viral activity of rhCC10 through chemical modification with ROS, RNS, and enzyme-catalyzed amino acid modification. The invention further pertains to enhancing the inhibition of neutrophil migration by rhCC10 through chemical modification with ROS, RNS, and enzyme-catalyzed amino acid modification.
Secretoglobins are a family of structurally related proteins comprised of four helical bundle monomers that form disulfide dimers, tetramers and higher multimers. There are 8 known human secretoglobins (
The primary source of CC10 in mammals is the pulmonary and tracheal epithelia, especially the non-ciliated bronchiolar airway epithelial cells (primarily Clara cells), and it is the most abundant locally-produced protein in the extracellular fluids of the adult lung. It is also secreted in the nasal epithelia. CC10 is also present in serum and urine, which is largely derived from pulmonary sources. CC10 is also produced by reproductive tissues (uterus, seminal vesicles), exocrine glands (prostate, mammary gland, pancreas), endocrine glands (thyroid, pituitary, adrenal, and ovary) and by the thymus and spleen (Mukherjee, 1999; Mukherjee, 2007). The major recoverable form of human CC10 in vivo is a homodimer, comprised of two identical 70 amino acid monomers, with an isoelectric point of 4.7-4.8. Its molecular weight is 15.8 kDa, although it migrates on SDS-PAGE at an apparent molecular weight of 10-12 kDa. In the native homodimer, the monomers are arranged in an antiparallel configuration, with the N-terminus of one adjacent to the C-terminus of the other and are connected by two disulfide bonds between Cys3 of one monomer and Cys69 of the other monomer (Mukherjee, 1999).
There are many chemical and enzymatic processes that modify amino acid residues on proteins. The secretoglobins undergo cleavage of N-terminal signal peptides, which is an integral part of the secretion process in mammalian cells. But they are not known to be glycosylated or lipidated. However, secretoglobins are subjected to the same processes that affect all other proteins in the extracellular milieu during an inflammatory response. Native CC10 is chemically modified in vivo and new forms of native CC10 have been identified in patient samples that are not present in samples from normal humans (Lindhal, 1999; Ramsay, 2001; Ariaz-Martinez, 2012). The modifications are presumed to be caused by inflammatory processes, since the new forms have only been identified in airway lining fluid (ALF) samples from patients with respiratory conditions characterized by ongoing or acute inflammation. Although some have speculated that the modifications to CC10 are the result of reactions with reactive oxygen species generated by the inflammatory response, the nature of the modifications is presently unknown. Furthermore, oxidative modification to native CC10 is thought to represent damage to the protein that impairs its anti-inflammatory activity and immunomodulatory function, thereby contributing to the development of chronic lung disease in premature infants who experience respiratory distress (Ramsay, 2001).
Synthetic CC10 protein may be made by recombinant or chemical synthetic methods (Barnes, 1996; Mantile, 1993; Nicolas, 2005). CC10 is the most well-known member of a family of structurally related proteins collectively called secretoglobins (Klug, 2000). The amino acid sequences for the mature secreted sequences of eight human secretoglobins are shown in
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are generated as a part of chronic inflammatory processes associated with aging and disease, or as a result of severe inflammatory responses to combat infections and other acute insults, such as smoke inhalation. Common ROS and RNS chemical reagents that mediate protein oxidation in vivo include hydrogen peroxide (H2O2), Fe2+, Cu1+, glutathione, HOCl, HOBr, 1O2, and ONOO−. ROS and RNS may be synthesized or released in vivo as a result of enzyme activity, such as myeloperoxidase, xanthine oxidase, and P-450 enzymes, and oxidative burst activity of activated phagocytic cells. Lipid peroxides such as 4-hydroxy-2-trans-nonenal (HNE), (MDA), and acrolein are the products of reactions of ROS and RNS with lipids that are, in turn, highly reactive and can form adducts with proteins. Ozone and UV light, as well as gamma irradiation in the presence of O2 and mitochondrial electron transport chain leakage, also cause protein oxidation.
ROS and RNS are indiscriminate chemically reactive agents that destroy essential biological components including nucleic acids, lipids (including membrane and surfactant phospholipids), and proteins, in both the pathogen and host, often causing significant tissue damage that may be more life-threatening than the original infection or other cause of the inflammatory response. For example, acute respiratory distress syndrome (ARDS) is often triggered by an acute lung infection (pneumonia) that results in the release of ROS and RNS, and typically has a 40-60% mortality rate due to pulmonary tissue damage that compromises lung function, even after the pathogen causing the infection is brought under control using anti-microbial agents.
There are several types of oxidative protein modifications, the most common of which is sulfur oxidation in which disulfide bonds between cysteines (Cys), S-thiolation, and methionine (Met) sulfoxide are formed. Protein carbonyl groups are also common oxidative modifications in which amino acid side chains are converted to aldehydes and ketones, especially lysine (Lys) arginine (Arg), and proline (Pro). Aliphatic amino acids may be converted to their hydro(pero)xy derivatives. Chloramines and deaminations may occur. Certain amino acids may be converted into other amino acids, such as histidine (His) to asparagine (Asn), while others may form lipid peroxidation adducts, amino acid oxidation adducts (eg. p-hydroxyphenylacetaldehyde), and glycoxidation adducts (eg. carboxymethyllysine). At a macroscopic protein level, cross-links, aggregation, and peptide bond cleavage may occur as a result of exposure to ROS and RNS.
There 12 amino acids that are modified in vivo by ROS and RNS into several physiologic oxidation products, as shown in Table 1. In general, amino acids cysteine (Cys) and methionine (Met) are the most susceptible to oxidation and, unlike oxidation of other amino acids, the oxidation of Met and Cys are reversible (methionine sulfoxide reductase and glutathione and thioredoxin redox systems) (Stadtman, 2002).
Modification of secretoglobins may also be mediated enzymatically, not just by the downstream effects of ROS and RNS generated by enzymes such as MPO, but also by transglutaminase enzymes (TGs). TGs are ubiquitous in nature, found in all forms of life from microbes to mammals. TGs are essential to several inter- and intracellular processes in mammals, including extracellular matrix synthesis, neutrophil and monocyte adhesion and motility, receptor endocytosis, pinocytosis, antigen uptake and processing, blood clotting, G-protein signaling, and apoptosis (reviewed in Lorand, 2003). TGs are multi-functional enzymes that mediate at least one main enzymatic activity; the classical transglutaminase activity in which a glutamine residue in one protein serves as an acyl donor and a lysine residue in a second protein serves as the acyl acceptor. TGs also mediate deamidation and esterification of proteins, as well as the creation and rearrangement of disulfide bonds between cysteine residues. None of these activities has an energy requirement and the only cofactor necessary is calcium.
Transglutaminases play a significant role in inflammation and immunity, particularly TG2 or tissue transglutaminase. It is present mostly in the cytoplasm but a portion of the enzyme is associated with the membrane on the cell surface and is known to be a coreceptor for fibronectin. TGs have also been shown to cross-link proteins to specific lipid moieties in membranes, allowing a lipid barrier to be created on a structural protein scaffold in skin (Lesort, 2000; Nemes, 1999). More recently, the emerging role of TGs in viral infection has been recognized (reviewed in Jeon, 2006). Intracellular TG2 is normally present in an inactive state and is activated by oxidative stress and calcium mobilization resulting from viral infection. Activated intracellular TG2 mediates its anti-viral activities via direct modification/inactivation of viral proteins, as well as modification of cellular proteins required for viral entry, replication, assembly, or transport. CC10 has been previously shown to be a substrate for TG2 (Mukherjee, 1988). CC10 is cross-linked to other CC10 molecules by TG2, to form covalently attached multimers and aggregates observed on SDS-PAGE gels and Western blots. However, no other TG-mediated reaction products of CC10 or other secretoglobin have been characterized.
The foregoing provides a non-exclusive list of the objectives achieved by the present invention:
A primary object of the invention is a composition of matter comprised of an oxidatively or enzymatically modified synthetic secretoglobin (whether made by recombinant or chemical methods).
A further object of the invention is a composition of matter comprised of an oxidatively or enzymatically modified synthetic CC10 (whether made by recombinant or chemical methods).
A further object of the invention is a composition of matter comprised of an oxidatively or enzymatically modified synthetic SCGB3A2 (whether made by recombinant or chemical methods).
A further object of the invention is a composition of matter comprised of an oxidatively or enzymatically modified synthetic SCGB3A1 (whether made by recombinant or chemical methods).
A further object of the invention is a composition of matter comprised of an oxidatively or enzymatically modified synthetic SCGB2A1 (whether made by recombinant or chemical methods).
A further object of the invention is a composition of matter comprised of an oxidatively or enzymatically modified synthetic SCGB2A2 (whether made by recombinant or chemical methods).
A further object of the invention is a composition of matter comprised of an oxidatively or enzymatically modified synthetic SCGB1D1 (whether made by recombinant or chemical methods).
A further object of the invention is a composition of matter comprised of an oxidatively or enzymatically modified synthetic SCGB1D2 (whether made by recombinant or chemical methods).
A further object of the invention is a composition of matter comprised of an oxidatively or enzymatically modified synthetic SCGB1D4 (whether made by recombinant or chemical methods).
A further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more methionine sulfoxides.
A further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more cysteine glutathiolates.
A further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more HNE-cysteines.
A further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more nitrotyrosines.
A further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more di-tyrosines.
A further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more carbonyl groups.
A further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing a combination of two or more modified amino acids selected from the groups consisting of methionine sulfoxide, nitrotyrosine, or di-tyrosine.
A further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more chlorotyrosines.
A further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more hydroxyprolines, pyrrolidones, or glutamic semialdehydes.
A further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more 2-amino-3-ketobutyric acids.
A further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more chloramines.
A further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more □-aminoadipic semialdehyde, chloramines, MDA-Lys, HNE-Lys, acrolein-Lys, carboxymethyllysine, or pHA-Lys.
A further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more hydroxytryptophan, nitro-tryptophan, or kynurenines.
A further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more valine or leucine peroxides.
A further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more oxalic or pyruvic acids.
A further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more hydroxyphenylalanines.
A further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more glutamic semialdehydes.
A further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more 2-oxohistidine or HNE-His.
A further object of the invention is a composition of matter containing a combination of an unmodified synthetic secretoglobin and an oxidatively or enzymatically modified synthetic secretoglobin, wherein the unmodified and modified preparations are the same secretoglobin.
A further object of the invention is a composition of matter containing a combination of an unmodified synthetic secretoglobin and an oxidatively or enzymatically modified synthetic secretoglobin, wherein the unmodified and modified preparations are not the same secretoglobin.
A further object of the invention is a composition of matter containing a combination two or more oxidatively or enzymatically modified synthetic secretoglobins, wherein the unmodified and modified preparations are the same secretoglobin.
A further object of the invention is a composition of matter containing a combination two or more oxidatively or enzymatically modified synthetic secretoglobins, wherein the unmodified and modified preparations are not the same secretoglobin.
A further object of the invention is a composition of matter containing a combination one or more unmodified synthetic secretoglobin and one or more oxidatively or enzymatically modified synthetic secretoglobins, wherein the unmodified and modified preparations are the same secretoglobin.
A further object of the invention is a composition of matter containing a combination one or more unmodified synthetic secretoglobin and one or more oxidatively or enzymatically modified synthetic secretoglobins, wherein the unmodified and modified preparations are not the same secretoglobin.
A secondary object of the invention is a pharmaceutical composition containing a modified synthetic secretoglobin that can be used as a therapeutic agent.
A further object of the invention is a pharmaceutical composition containing a combination of two or more modified synthetic secretoglobins that can be used as a therapeutic agent.
A further object of the invention is a pharmaceutical composition containing a combination of unmodified and modified synthetic secretoglobins that can be used as a therapeutic agent.
It is a further object of the invention to administer a modified synthetic secretoglobin to a patient with an inflammatory condition or a viral infection.
It is a further object of the invention to administer a modified synthetic secretoglobin to a patient with a respiratory disease or condition, an autoimmune disease or condition, a fibrotic condition, a metabolic disease, an infectious disease, or any acute or chronic inflammatory condition or disease.
It is a further object of the invention to administer a modified synthetic secretoglobin to a patient any condition characterized by a deficiency of the native secretoglobin isoform corresponding to the modified synthetic secretoglobin to be administered.
It is a further object of the invention to administer a modified synthetic secretoglobin to treat or prevent a severe exacerbation of an underlying condition in a patient with an underlying chronic disease or condition.
It is a further object of the invention to administer a modified synthetic CC10 to a patient with an inflammatory condition or a viral infection.
It is a further object of the invention to administer a modified synthetic CC10 to a patient with a respiratory disease or condition, an autoimmune disease or condition, a fibrotic condition, a metabolic disease, an infectious disease, or any acute or chronic inflammatory condition or disease.
It is a further object of the invention to administer a modified synthetic CC10 to a patient any condition characterized by a deficiency of the native CC10 isoform corresponding to the modified synthetic CC10 to be administered.
It is a further object of the invention to administer a modified synthetic CC10 to treat or prevent a severe exacerbation of an underlying condition in a patient with an underlying chronic disease or condition.
It is another object of the invention to use a modified synthetic secretoglobin that can be used to develop a diagnostic assay to evaluate patient samples.
It is further object of the invention to use a modified synthetic secretoglobin as a standard that can be used in a diagnostic assay to evaluate patient samples.
It is further object of the invention to use a modified synthetic CC10 that can be used to develop a diagnostic assay to evaluate patient samples.
It is a further object of the invention to use a modified synthetic CC10 in a standard that can be used in a diagnostic assay to evaluate patient samples.
It is a further object of the invention to use a modified synthetic secretoglobin as a standard to enable the purification of a modified native secretoglobin from a biological source such as blood, urine, or tissue.
It is a further object of the invention to use a modified synthetic secretoglobin as a standard to enable the development of a process to purify of a modified native secretoglobin from a biological source such as blood, urine, or tissue.
It is a further object of the invention to use a modified synthetic secretoglobin as a standard to monitor a process to purify of a modified native secretoglobin from a biological source such as blood, urine, or tissue.
It is a further object of the invention to use a modified synthetic secretoglobin as a standard to control the quality of a modified native secretoglobin purified from a biological source such as blood, urine, or tissue.
A further object of the invention is a process in which chemical oxidation is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
A further object of the invention is a process in which a reactive oxygen species (ROS) is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
A further object of the invention is a process in which a reactive nitrogen species (RNS) is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
A further object of the invention is a process in which sodium hypochlorite (NaOCl) is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
A further object of the invention is a process in which hypochlorite (HOCl) is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
A further object of the invention is a process in which metachloroperbenzoic acid (mCPBA) is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
A further object of the invention is a process in which hydrogen peroxide (H2O2) is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
A further object of the invention is a process in which an unmodified synthetic secretoglobin or secretoglobin purification intermediate of an unmodified synthetic secretoglobin is converted into a modified synthetic secretoglobin or secretoglobin purification intermediate by oxidation mediated by contact with a metal ion.
A further object of the invention is a process in which an unmodified synthetic secretoglobin or secretoglobin purification intermediate of an unmodified synthetic secretoglobin is converted into a modified synthetic secretoglobin or secretoglobin purification intermediate by oxidation mediated by contact with a nickel ion.
A further object of the invention is a process in which an unmodified synthetic secretoglobin or secretoglobin purification intermediate of an unmodified synthetic secretoglobin is converted into a modified synthetic secretoglobin or secretoglobin purification intermediate by oxidation mediated by contact with an iron ion.
A further object of the invention is a process in which an unmodified synthetic secretoglobin or secretoglobin purification intermediate of an unmodified synthetic secretoglobin is converted into a modified synthetic secretoglobin or secretoglobin purification intermediate by oxidation mediated by contact with a copper ion.
A further object of the invention is a process in which an unmodified synthetic secretoglobin or secretoglobin purification intermediate of an unmodified synthetic secretoglobin is converted into a modified synthetic secretoglobin or secretoglobin purification intermediate by oxidation mediated by contact with a cobalt ion.
A further object of the invention is a process in which an enzyme is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
A further object of the invention is a process in which myeloperoxidase is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
A further object of the invention is a process in which transglutaminase is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
A further object of the invention is a process in which transglutaminase is used to attach a label, chemical, lipid, or peptide moiety to an unmodified synthetic secretoglobin.
The invention relates to chemical and/or enzymatic modification of synthetic secretoglobins in order to alter or enhance biological or biochemical properties compared to the unmodified versions. Chemical reagents such as reactive oxygen species (ROS), and reactive nitrogen species (RNS), or enzymes such as myeloperoxidase or transglutaminase, are used to achieve the amino acid modifications. The addition of lipid and other moieties to secretoglobins is also mediated by TGs. The invention further relates to optimization of chemical or enzyme-mediated processes to achieve amino acid modifications, as well as biochemical and physical characterization of mixtures of modified secretoglobins, and isolation and characterization of individual secretoglobin isoforms. The term “isoform” herein refers to a secretoglobin monomer, dimer, or other multimer complex that contains monomer units of at least 60 amino acids in length, but preferably full length monomers that are at least 75% identical to the amino acid sequences shown in
The amino acid sequences of the monomer forms of eight human secretoglobins are shown. All sequences were taken from Genebank and signal peptides of the translation products have been removed to show the predicted N-termini of each monomer. All secretoglobins share a conserved four helical bundle secondary structure and form homodimers, heterodimers, tetramers, and large multimers.
Preparations of unmodified rhCC10 (panel A) and rhCC10 reacted with increasing amounts of NaOCl oxidant equivalents (panels B-E) were analyzed by reverse phase HPLC using a C-18 column. The arrow points to the unmodified rhCC10 peak in reaction mixtures. Approximately 25 mcg of protein was loaded for each HPLC run shown. Panel A-E depict HPLC analysis of NaOCl oxidation products.
A 10-20% tricine SDS-PAGE gel was used. Preparations of rhCC10 modified with increasing amounts of NaOCl; numbers of oxidant equivalents are shown for each lane. All samples, each containing ˜5 mcg protein, were reduced with 1 mM DTT in SDS loading buffer and heated to 65° C. for 15 minutes prior to gel loading.
The IEF gel covered pH range from 3-7. Preparations of rhCC10 modified with increasing amounts of NaOCl; numbers of oxidant equivalents are shown for each lane. All samples contain ˜25 mcg protein. Samples were not reduced, exposed to SDS, or heated prior to gel loading.
The IEF gel covered pH range from 3-7 and was blotted to PVDF membrane, then probed with a Protein-A purified rabbit polyclonal antibody prepared using unmodified rhCC10 as the antigen. Preparations of rhCC10 modified with NaOCl reaction conditions shown in lane descriptions. All samples contain −25 mcg protein. Samples were not reduced, exposed to SDS, or heated prior to gel loading.
A 10-20% tricine SDS-PAGE gel was run on the modified rhCC10 preparations. NaOCl reaction products were run alongside MPO and mCPBA reaction products. The gel was blotted to PVDF then probed with rabbit polyclonal anti-DNP antibody (commercially available). Samples were not reduced but were mixed with SDS PAGE loading buffer and heated to 65° C. for 15 minutes prior to loading. Unmodified rhCC10 and MPO and mCPBA reaction products were not recognized by the antibody under the conditions used. Only the NaOCl reaction products contained detectable DNP, indicating the presence of carbonyl groups in these preparations.
Preparations of unmodified rhCC10 (
The IEF gel covered pH range from 3-7. Preparations of rhCC10 modified with increasing amounts of mCPBA; numbers of oxidant equivalents are shown for each lane and two different temperatures were tested. All samples contain ˜25 mcg protein. Samples were not reduced, exposed to SDS, or heated prior to gel loading.
The IEF gel covered pH range from 3-7 and was blotted to PVDF membrane, then probed with Protein-A purified rabbit polyclonal antibody raised against rhCC10. Preparations of rhCC10 modified with increasing amounts of mCPBA; numbers of oxidant equivalents are shown for each lane and two different temperatures were tested. All samples contain ˜25 mcg protein. Samples were not reduced, exposed to SDS, or heated prior to gel loading.
The IEF gel covered pH range from 3-7. Preparations of rhCC10 modified with mCPBA under additional conditions, including the presence of CaCl2) and comparison of much higher numbers of oxidant equivalents. All samples contain −25 mcg protein. Samples were not reduced, exposed to SDS, or heated prior to gel loading.
C-18 RP-HPLC was used to separate each of eight individual CC10 isoforms represented as different peaks from the mCBPA reaction mixture. In this example, peak #3 (
MPO-H2O2 reactions with and without 2 mM CaCl2) (respectively panels A, B, D and panels C, E) were compared using C-18 RP-HPLC to monitor reactions. All reactions were performed in the dark in citrate buffer at pH 5.0 with 50 oxidant equivalents of H2O2 at 37° C. for a total of 60 minutes. Arrows point out peaks corresponding to unmodified rhCC10. All samples contain ˜25 mcg protein.
MPO-H2O2 reactions with 2 mM CaCl2) (panels B-E). were monitored using C-18 RP-HPLC with increasing amounts of MPO and H2O2. All reactions were performed in the dark in citrate buffer at pH 5.0 with 50 oxidant equivalents of H2O2 at 37° C. for a total of 30 minutes. Arrows point out peaks corresponding to unmodified rhCC10. All samples contain ˜25 mcg protein.
The IEF gel covered pH range from 3-7. Preparations of rhCC10 modified with increasing amounts of MPO. All reactions were performed in the dark in citrate buffer at pH 5.0 with 50 oxidant equivalents of H2O2 at 37° C. for a 1 or 24 hours. All samples contain ˜25 mcg protein. Samples were not reduced, exposed to SDS, or heated prior to gel loading.
The IEF gel covered pH range from 3-7 and was blotted to PVDF membrane, then probed with Protein-A purified rabbit polyclonal antibody raised against rhCC10. Preparations of rhCC10 modified with increasing amounts of MPO. All reactions were performed in the dark in citrate buffer at pH 5.0 with 50 oxidant equivalents of H2O2 at 37° C. for a 1 or 24 hours. All samples contain ˜25 mcg protein. Samples were not reduced, exposed to SDS, or heated prior to gel loading.
C-18 RP-HPLC was used to separate each of eight individual CC10 isoforms represented as different peaks, numbered 9-17, from the MPO-H2O2 reaction mixture (panel B). In this example, peak #10 was collected, rerun on the HPLC to estimate purity, then sent for mass spectral analysis (electrospray ionization method). The arrow points out the peak that was purified in this example. All samples contain ˜25 mcg protein. Results of ESI-MS analysis are shown in Panel D.
Reactions of rhCC10 with peroxynitrite were monitored using C-18 RP-HPLC with increasing numbers of oxidant equivalents (panels B-E). Reactions were performed in water at room temperature in the dark for 1 hour. The arrow points out the peak corresponding to unmodified rhCC10. All samples contain ˜25 mcg protein.
Reactions of rhCC10 with peroxynitrite in the presence of CaCl2) (panels A,C,E,G) and absence of CaCl2) (panels B,D,F,H) and at different pHs were monitored using C-18 RP-HPLC with increasing numbers of oxidant equivalents. Reactions were performed using 10 oxidant equivalents at room temperature in the dark for 1 hour. Arrows point out peaks corresponding to unmodified rhCC10. All samples contain ˜25 mcg protein.
A 10-20% tricine SDS-PAGE gel was run on the modified rhCC10 preparations. The gel was blotted to PVDF then probed with rabbit polyclonal anti-nitrotyrosine antibody (commercially available). Samples containing 10 mcg protein were not reduced but were mixed with SDS PAGE loading buffer and heated to 65° C. for 15 minutes prior to loading. Unmodified rhCC10 was not recognized by the antibody.
Schematic diagrams of oxidative modification reaction products observed with rhCC10; addition of oxygen to methionine, addition of nitro group to tyrosine, formation of carbonyl groups that are reactive with DNPH.
Western blot of in vitro reactions of rhCC10 using TG2+4.5 mM calcium with two different biotinylated amine compounds. The reactions were performed in 25 mM Tris/150 mM NaCl pH 8.0 with 1.5 mM DTT at using 5 micro-units of TG2 enzyme at 37° C. for 60 minutes. Reactions were run on a 10-20% SDS-PAGE tricine gel, blotted to PVDF membrane, and probed with streptavidin-HRP conjugate, which recognizes the biotin. All lanes contain reducing agent to eliminate disulfide bonds.
Neutral red assay indicating cell survival with and without infection by two strains of influenza (H1N1: Neutral Red Assay,
Fluorescence measurements of migrated differentiated PLB-985 cells differentiated in the presence of 100 mcg/ml of unmodified rhCC10 (CC10-A), NaOCl-modified rhCC10 (CC10-B), and mCBPA-modified rhCC10 (CC10-C).
Secretoglobin: A type of protein that includes human and non-human proteins in the CC10 family having the conserved four helical bundle motif and ranging in size from about 50-100 amino acids in length. Human secretoglobins are shown in
Synthetic secretoglobin: A secretoglobin that is made by chemical or recombinant process and not isolated from a natural source.
Unmodified secretoglobin protein: A secretoglobin monomer, dimer, or other multimer that does not contain chemically or enzymatically modified amino acid residues, other than spontaneously occurring disulfide bonds between cysteine residues in homodimers and heterodimers.
Unmodified CC10 protein: A CC10 monomer, dimer, or other multimer that does not contain chemically or enzymatically modified amino acid residues, other than disulfide bonds between cysteine residues.
Modified secretoglobin: A secretoglobin monomer, dimer, or other multimer, that contains one or more chemically or enzymatically modified amino acid residues.
Modified synthetic secretoglobin: A synthetic secretoglobin monomer, dimer, or other multimer, that contains one or more chemically or enzymatically modified amino acid residues.
Modified CC10: A CC10 monomer, dimer, or other multimer, that contains one or more chemically or enzymatically modified amino acid residues.
Modified recombinant human CC10: A CC10 monomer that is made by recombinant DNA methods and contains one or more chemically or enzymatically modified amino acid residues.
Modified synthetic CC10: A CC10 monomer made by either recombinant DNA or chemical peptide synthetic methods that contains one or more chemically or enzymatically modified amino acid residues.
Modified amino acid residues: An amino acid in a protein whose side chain has been modified from the form originally present upon completion of translation of the protein.
The chemical structure of the 20 natural unmodified amino acids found in proteins can be found in any biochemistry textbook.
Carbonyl group: An aldehyde or ketone group on an amino acid side chain.
The modification of secretoglobins by ROS, RNS, and enzymatic activity such as MPO and TG2 has not been investigated in detail. Preliminary reports suggest that native CC10 is modified during acute inflammatory responses in vivo, such as in respiratory distress, giving rise to new isoforms thus far identified by cross-reactivity with anti-CC10 antibodies and isoelectric points different from unmodified CC10 (pI˜4.8), which is the predominant form in biological fluid samples. It has also been reported that CC10 is a substrate for tissue transglutaminase in vitro. Other than the role for Cys residues in stabilizing multimers and controlling access to the central hydrophobic cavity, there is no known physiological role for oxidation of any amino acid in any secretoglobin. We believe that reversible oxidation of Cys and Met residues is a protective physiologic mechanism by which CC10 and other secretoglobins are able to scavenge harmful ROS from the local environment, thereby sparing tissue during an inflammatory response. We further believe that the oxidation status of Cys and Met residues in secretoglobins affects the biochemical and biological properties but does not represent protein damage that results in loss of function, rather the properties and function of the oxidized secretoglobins are modulated. Likewise, oxidative and/or enzymatic modification of other secretoglobin amino acids such as tyrosine, lysine, glutamine, valine, leucine, phenylalanine, glutamate, arginine, threonine, proline, histidine, and tryptophan do not represent protein damage, but rather modulate biochemical and biological properties that enable different or enhanced activities.
The majority of known, specific ROS, RNS, and MPO-mediated amino acid modifications are associated with protein damage and loss of function. Accumulation of oxidized protein is associated with disease and aging processes (Berlett and Stadtman, 1997). However, recognition of reversible oxidation is emerging as a regulatory mechanism for modifying protein function and not just a form of damage that inactivates proteins. All eight human secretoglobins contain Cys residues that are believed to typically exist in a naturally oxidized state in which disulfide bonds between conserved cysteines at the N- and C-termini stabilize homo- and hetero-dimers, tetramers, and higher multimers. All cysteines in secretoglobins are potentially susceptible to oxidation and the formation of intra- or intermolecular disulfide bonds, particularly the respiratory secretoglobins, CC10, SCGB3A1, and SCGB3A2. The disulfide bonds between N- and C-terminal Cys in CC10 certainly stabilize the homodimer in conditions that would otherwise break apart the dimer into monomers, such as in non-reducing SDS-PAGE conditions. Similarly, the internal Cys of SCGB3A2 (Cys60 of the sequence shown in
A physiological role for CC10 has been proposed to be the scavenging of toxic or otherwise harmful hydrophobic moieties that may be taken up and bound into the central hydrophobic cavity and thereby removed from the local tissue environment (Peter, 1992; Hard, 1995; Umland, 1992; 1994). The disulfide bonds between the Cys residues (Cys3 and Cys69) of the monomer components in each CC10 dimer are believed to act like a gate that opens and closes by reversible oxidation of the Cys residues to form and break the disulfide bonds to allow entry of a hydrophobic moiety into the central hydrophobic cavity, then trap it there. Several studies have reported the strong binding of putative in vivo CC10 ligands such as a polychlorinated biphenyls and progesterone, inside the dimer and that specific residues such as Phe6 and Tyr21 stabilize ligand binding (Callebaut, 2000).
All secretoglobins contain significant proportions of amino acids that are susceptible to oxidative and enzymatic amino acid modification. Each 70 amino acid monomer of CC10 contains a total of 42 amino acids (out of 70; >50%), listed in Table 1, that can be oxidized by physiologic processes involving ROS and RNS, leaving open the possibility of a large number of ROS and RNS reaction products, aka isoforms. TG can also be used to attach lipid or other moieties to secretoglobins via their glutamine, lysine, and cysteine residues, and not just cross-link secretoglobins to other proteins. As illustrated in the following examples, we have herein found this to be the case with rhCC10, in which oxidative and enzymatic modifications give rise to multiple isoforms that can be isolated and characterized. Preparations containing oxidatively modified rhCC10 also mediated enhanced of inhibition of viral replication and neutrophil chemotaxis, representing significant improvements on the existing unmodified CC10 drug preparation. Furthermore, the use of rhCC10 preparations modified in vitro as standards to assess CC10 isoforms contained within, or isolated from, biological samples, enables the evaluation of native CC10 isoforms as biomarkers of pulmonary status in chronic diseases and acute conditions. Thus, in the absence of oxidative or enzymatic amino acid modification, a secretoglobin may have no effect on a particular cell type, but has a different effect after modification because the modification enabled or disabled binding to a cell surface receptor, cell signaling molecule, lipid, ligand, structural protein, or other intra- or extracellular component. The effects of oxidative and/or enzymatic amino acid modification on the biochemical and biological properties of secretoglobins, therefore, opens up new possibilities for the use of modified secretoglobins in mediating pharmacological effects not previously possible using unmodified preparations, as well as for use as standards to evaluate novel isoforms of native secretoglobins as biomarkers of disease status in various patients, including, but not limited to patients with cancer, respiratory diseases, autoimmune diseases, acute or chronic infections, allergies, metabolic diseases, cardiovascular diseases, hematologic disorders, and exposures to smoke, chemical pollutants, toxins or other insult.
Each reaction was initiated at ˜4° C. (on ice) by adding NaOCl (9.2 □L; 0.05% solution in water, 62.1 nmol, 5 equivalents) to a solution of the protein (0.2 mg, 12.42 nmol) in 10 mM phosphate buffer, pH 7.4 or plain water, mixing briefly and incubating on ice for 15 minutes in the dark (total volume of 0.2 mL). The reaction was quenched by adding L-methionine (9.3 □L; 10 mM in water, 93.15 nmol), then incubated for 20 min and warmed to room temperature.
Several reactions were performed using equivalents of the oxidant (“oxidant equivalents”) ranging from 1-100
Increasing the number of oxidant equivalents of NaOCl increased the number of rhCC10 isoforms as well as the peak heights, indicating increased amounts of each isoform as the reaction progressed. At 20 oxidant equivalents, the HPLC shows that essentially all of the unmodified rhCC10 is gone and only modified isoforms remain. SDS-PAGE of these preparations under reducing conditions showed monomeric protein (6 kDa) as expected, but also showed dimer (˜12 kDa), tetramer (˜24 kDa), hexamer (˜32 kDa), and higher multimer bands remaining, as shown in
Interactions of the modified and unmodified rhCC10 with the C-18 column reflect hydrophobic interactions between the protein and chromatography resin. The modified isoforms elute faster than the unmodified rhCC10, indicating that the amino acid residues on the surface of the modified protein are less hydrophobic than the unmodified protein. Changes in the surface hydrophobicity pattern likely correspond with changes in surface charge, which can be measured by the isoelectric point. Samples were analyzed by isoelectric focusing using pH 3-7 isoelectric focusing gels as shown in
The extent of the chemical reaction and modification of rhCC10 can be estimated by the detection of reactive carbonyl groups. The presence of carbonyl groups in ROS-reacted rhCC10 samples can be detected by labeling the carbonyl groups with 2,4-dinitrophenylhydrazine (DNPH), which adds a dinitrophenylhydrazone group (DNP), then analyzing the reaction products by Western blot using anti-DNP antibody as shown in
Each reaction was initiated at ˜24° C. (room temperature) by adding meta-choloroperbenzoic acid (mCPBA) (6.21 □L, 2 mM in water, 12.42 nmol, 2 equivalents) in 1 portion to a solution of the protein (0.1 mg, 6.21 nmol) in water at 24° C. and incubating for 15 minutes in the dark with occasional stirring (total volume of 0.2 mL). The reaction was stopped by the addition of L-methionine (1.8 □L; 10 mM in water, 18.6 nmol) and incubated for 20 min at 24° C. Several reactions were performed using oxidant equivalents of mCPBA ranging from 2-100.
Oxidation of rhCC10 was monitored using HPLC. Reactions were concentrated in a Speedvac and then resuspended in water. Approximately 25 □g of each sample was injected onto the HPLC, as with the NaOCl reactions. New modified isoforms appeared as new HPLC peaks, eluting earlier than unmodified rhCC10, as shown in
In order to further characterize the CC10 isoforms generated in the mCPBA reaction, a protein sample of each of 8 separate major HPLC peaks (numbered 1-8) was collected, concentrated using a Speedvac, and verified by repeat HPLC to represent a single peak; for example peak 3, as shown in
Modification of rhCC10 by MPO plus H2O2 was monitored using HPLC. The reaction of rhCC10 with MPO-H2O2 required extensive optimization before any CC10 modifications were observed. Initial reactions performed in phosphate buffered saline (PBS), pH 7.4, in the absence of calcium chloride (CaCl2)) were unsuccessful. Very modest increases in the number and height of new HPLC peaks were achieved in phosphate buffer at neutral pH with increasing amounts of MPO and H2O2. However, the lowering of pH to 5 using citrate buffer and the addition of CaCl2) dramatically increased the CC10 reaction products detectable as new HPLC peaks as shown in
Isoelectric focusing of the MPO and H2O2 reactions, shown in
In order to further characterize the CC10 isoforms generated in the MPO-H2O2 reactions, a protein sample of each of 8 major separable HPLC peaks (numbered 9-17) was collected, concentrated using a Speedvac, and verified by repeat HPLC to represent a single peak; for example peak 10, as shown in
Modification of rhCC10 by peroxynitrite was monitored using HPLC. Each reaction was initiated at ˜23° C. (room temperature) by adding commercially available peroxynitrite reagent (10-100 equivalents) to 0.1 mg of protein (total reaction volume 0.2 mL), stirring briefly and incubating for 1h in the dark. Reactions were typically concentrated in a Speedvac, then resuspended in water, and about 25 □g of each sample was injected onto the HPLC, as with the other reactions. Modified isoforms appeared as new HPLC peaks, eluting both earlier and later than unmodified rhCC10, as shown in
Each human CC10 monomer contains a single tyrosine, which these results show is susceptible to nitration in the presence of RNS without the need to denature the protein with 8M urea, or elevate the reaction pH to 8.5-9.0, as previously observed using native rabbit uteroglobin and tetranitromethane instead of RNS (peroxynitrite) (Saavedra, 1980). As the reaction with peroxynitrite progresses, intermolecular bonds may form di-tyrosine complexes in different monomers. The isoforms generated by the peroxynitrite reactions were largely intact human CC10 homodimer with larger covalently linked complexes as shown by Western blot of SDS-PAGE in
The results herein (Examples 1-4) demonstrate that multiple reactive oxygen or nitrogen species may be used in the process to produce a ROS- or RNS-modified secretoglobin, such reactive oxygen or nitrogen species including but not limited to hypochlorite, sodium hypochlorite, mCPBA, peroxynitrite, nitric oxide, hydrogen peroxide, oxygen, ozone, chlorine, fluorine, bromine, iodine, permanganate (MnO4), chromate (CrO4), dichromate (Cr2O7) ions, nitric acid (HNO3), perchloric acid (HClO4), and/or sulfuric acid (H2SO4). The results demonstrate that the concentration of sodium (Na) used in the process to produce a ROS- or RNS-modified secretoglobin is about 0.9% on a weight to volume basis, but may range between 0.1% and 20%. Potassium (K) alone or in combination with sodium, may also be used at a concentration of 0.1%-20%. The process may also utilize a buffer such as phosphate, citrate, sulfate, Tris, HEPES, or MOPS in order to maintain the pH at a constant level between pH 3.0 and 9.0, but most optimally in the 6.5-7.5 range. Calcium and/or magnesium may also be used in the process to manipulate the secretoglobin conformation to produce specific isoforms.
The results herein further demonstrate that the preferred temperature of the process for ROS and RNS modification of a secretoglobin is close to 0° C., in the range of 0−8° C., and that the most useful range of molar ratios of CC10 molecules to oxidant equivalents ranges between 1:1 and 1:50. However, as the temperature is increased, the molar ratio of oxidant equivalents may be decreased and one would expect that changes in secretoglobin conformation at below normal body temperature (<32° C.), body temperature and fever range (>32-45° C.), and over physiologic temperatures (>45° C.) would impact process efficiency and the isoforms produced.
CC10 was shown to be an in vitro substrate of tissue transglutaminase (aka TG2) (Manjunath, 1984), and is cross-linked to itself and other proteins via glutamine and lysine residues. Determination of availability of glutamine in uteroglobin as an acyl donor/amine acceptor was performed using biotin linked to two different monoamine groups. Purified guinea pig liver transglutaminase and monoamine-biotin reagents; 5-(Biotinamido)pentylamine and (+)-Biotinyl-3,6-dioxaoctanediamine; were purchased from a commercial vendor. The reactions were performed in 25 mM Tris/150 mM NaCl pH 8.0 with 1.5 mM DTT. Where applicable, CaCl2) was used at a final concentration of 4.5 mM. Calcium is a TG cofactor required for the crosslinking of glutamine and lysine residues. In the absence of calcium and reducing agent, TG2 mediates a rearrangement of disulfide bonds in CC10, resulting in formation of a “ladder” of multimers that can be reduced with a reducing agent (not shown). The protein and amine of interest were combined in buffer with or without calcium to an assay volume of 0.1 mL. Samples were pre-incubated at 37° C. for 30 minutes prior to the addition of the transglutaminase. EDTA at a final concentration of 50 mM was added to the samples without calcium and acted as negative controls. After the pre-incubation 5 □U of transglutaminase was added to each tube and the reaction was allowed to proceed at 37° C. for 60 minutes. After 60 minutes EDTA (50 mM) was added to the tubes containing calcium to stop the reaction. One hundred □L of SDS sample buffer plus reducing agent (1 mM DTT) was added to each reaction, which were then heated at 95° C. for 10 minutes prior to separation on a SDS-PAGE gel. The gel was blotted to a PVDF membrane. Blocking was done for 1 hour at room temperature using 5% BSA (filtered through a 2 micron membrane). Washes between incubations were done with PBS-Tween (0.4%). Biotin groups were detected on the labeled protein(s) by incubating with a streptavidin-alkaline phosphatase conjugate. Visualization was performed with colorimetric reagents (NBT/BCIP) as shown in
In order to determine the effect of modification on the activity of rhCC10, a single pool of modified rhCC10 was made by combining equal aliquots of rhCC10 reactions with NaOCl, mCPBA, MPO+H2O2, and peroxynitrite. All HPLC peaks from each reaction were represented in the pool. Modified and unmodified rhCC10 preparations were diluted in eight half-log dilutions in MEM solution at the highest concentrations possible with the sample available. Each dilution was added to 5 wells of a 96-well plate with 80-100% confluent MDCK cells. Three wells of each dilution were infected with virus (H1H1 or H5N1), and two wells remained uninfected as toxicity controls. The multiplicity of infection (MOI) for each virus was between 0.1-1.0. Media was MEM solution with 10 units/mL trypsin. After untreated virus control wells reached maximum cytopathic effect (CPE), plates were then stained with neutral red dye for approximately 2 hours, then supernatant dye was removed from the wells and the incorporated dye was extracted in 50:50 Sorensen citrate buffer/ethanol, then the optical density at 540 nm was read on a spectrophotometer. Neutral red dye is taken up in live cells and used as a measure of cells remaining after viral infection. Results are shown in
Human PLB-985 cells are an immature myeloid leukemia cell line that can be differentiated in vitro essentially into mature human neutrophils (Pedruzzi, 2002). The differentiated PLB-985 cells can then be used as surrogates for actual human neutrophils isolated from peripheral blood in neutrophil function assays such as chemotaxis in response to a variety of stimuli, including fMLP. fMLP is a formylated peptide (Met, Leu, Pro) that is produced only by bacteria and is a signal of bacterial overgrowth to the body that elicits a potent anti-inflammatory response, including migration of neutrophils along a concentration gradient towards the source of the fMLP. Both unmodified and modified rhCC10 were evaluated as inhibitors of differentiated PLB-985 (dPLB-985) in this model.
Cells were grown in RPMI 1640 medium containing 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37° C. in a humidified atmosphere of 5% CO2. To induce a differentiation to the mature neutrophil phenotype, PLB-985 cells were cultured in medium supplemented with 300 μM dibutyril cyclic AMP for 3 days before each experiment. Differentiated PLB-985 cells were resuspended in RPMI-1640 (without phenol red) containing 10% FBS (RPMI/FBS) at 107 cells/ml. The cells were pre-incubated with 5 μg/ml calcein-acetoxymethyl ester at 37° C. for 30 min in the dark with constant agitation. The cells were then washed and resuspended in RPMI/FBS at 2×106 cells/ml. The dPLB-985 cells were incubated with 100 mcg/ml rhCC10 preparations at 37° C. for 60 min or PBS (50%). Cell migration was monitored using a 96-well ChemoTX disposable chemotaxis system (Neuro Probe). The wells of the lower chamber of the plate were filled with 32 μl of fMLP at 10−8 M. The polycarbonate filters (3 μM) were positioned on the plate, and dPLB-985 cells (30 μl; 60,000 cells/well) were placed on the filter and allowed to migrate for 120 min at 37° C. in the presence of 5% CO2 in the dark. The cells that had not migrated were removed by gently wiping the filters with a tissue.
The fluorescence of the cells in the filters was measured with a microplate fluorescence reader using excitation and emission wavelengths of 485 and 530 nm, respectively. The fluorescence from known numbers of dPLB-985 were obtained by placing them into the bottom chamber and a standard curve was generated (
Recombinant human CC10 was produced using a ubiquitin-like (UBL) fusion protein expression system in E. coli bacteria, as described in Examples 2 and 3 of U.S. Pat. No. 9,765,127, except that the human CC10 sequence according to
One of the functional consequences of ROS modification of human CC10 is that binding of Syndecan-4 (SDC4) is enhanced as described in Examples 3, 8, and 9 of U.S. patent application 62/925,058.
The data illustrate that the ROS-modified rhCC10, RNS-modified rhCC10, and T2-CC10 are essentially equivalent in binding to SDC4, while the unmodified rhCC10 binding to SDC4 is significantly lower. Since the T2-CC10 was not ROS or RNS modified after it was purified and no other steps in the purification allow either the fusion protein or the T2-CC10 to come into contact with any type of oxidizing agent, we infer that the oxidative modification took place during the exposure of the UBL-T2-CC10 fusion protein to metal ions. This observation has significant implications not only in that it is possible to produce a version of recombinant human CC10 that has the enhanced potency properties of ROS-modified or RNS-modified rhCC10 without having to perform the extra step of exposing the purified protein to ROS or RNS, but also that exposure to metal ions and/or surfaces, such as injection needles or other metal delivery device components, could positively or negatively impact the biological activities of the purified recombinant human CC10 protein.
This application is a continuation-in-part of U.S. patent application Ser. No. 16/896,213 filed Jun. 9, 2020, now abandoned which is a continuation of U.S. patent application Ser. No. 16/416,268, filed Jul. 17, 2016, patented as U.S. Pat. No. 10,676,513 B2 on Jun. 9, 2020, which is a continuation of U.S. patent application Ser. No. 15/212,277, filed on Jul. 17, 2016, patented as U.S. Pat. No. 10,294,285 B2 on May 21, 2019, which is a continuation of U.S. patent application Ser. No. 13/843,773, filed Mar. 15, 2013, patented as U.S. Pat. No. 9,394,349 B2 on Jul. 19, 2016, the disclosures of each of which are hereby incorporated by reference in their entireties.
| Number | Name | Date | Kind |
|---|---|---|---|
| 6953666 | Kinkade | Oct 2005 | B1 |
| 7655413 | Butt | Feb 2010 | B2 |
| 7846899 | Pilon | Dec 2010 | B2 |
| 8470767 | Pilon | Jun 2013 | B2 |
| 8501688 | Kimura | Aug 2013 | B2 |
| 9394349 | Pilon | Jul 2016 | B2 |
| 1029428 | Pilon-Clayton | May 2019 | A1 |
| 10676513 | Pilon-Clayton | Jun 2020 | B2 |
| 20010029025 | Dreyfuss | Oct 2001 | A1 |
| 20030008816 | Pilon | Jan 2003 | A1 |
| 20040047857 | Pilon | Mar 2004 | A1 |
| 20060275794 | Carrino | Dec 2006 | A1 |
| 20080063626 | Ding | Mar 2008 | A1 |
| 20090004684 | Maier | Jan 2009 | A1 |
| Number | Date | Country |
|---|---|---|
| 0617965 | Oct 1994 | EP |
| 2004101824 | Nov 2004 | WO |
| 2007109118 | Mar 2007 | WO |
| 2011047065 | Apr 2011 | WO |
| Entry |
|---|
| Giannone et al. “Oxidative modification of recombinant human Clara Cell Secretory Protein (rhCC10) by myeloperoxidase (MPO) and HOCI in vitro.” Pediatric Research 53;416A, Annual Meeting of the Pediatric Academic Societies, Seattle, WA USA. (Year: 2003). |
| Cai et al. “Preclinical evaluation of human secretoglobin 3A2 in mouse models of lung development and fibrosis” Am J Physiol Lung Cell Mol Physiol 306:L10-L22. (Year: 2014). |
| PCT Search Report and Written Opinion in PCT/US2014/030117 dated Sep. 29, 2014. |
| PCT International Preliminary Report on Patentability in PCT/US2014/030117 dated Mar. 2, 2015. |
| Levine, et al. Safety, Pharmacokinetics, and Anti-inflammatory Effects of Intratracheal Recombinant Human Clara Cell Protein in Premature Infants with Respiratory Distress Syndrome; Pediatric Research (Jul. 2005) 58, 15-21. |
| Vilaseca M et al., “Stepwise and Convergent Approaches to the Synthesis of the Uteroglobin Monomer, a 70 Amino Acid Peptide”, Peptides 1996, Proceedings of the European Symposium, Sep. 18-13, 1996, p. 873-874. |
| Antico, G., M. W. Lingen, A. Sassano, J. Melby, R. W. Welch, S. Fiore, A. L. Pilon and L. Miele. “Recombinant human uteroglobin/CC10 inhibits the adhesion and migration of primary human endothelial cells via specific and saturable binding to fibronectin.” J Cell Physiol 207(2): 553-561 (Dec. 2005). |
| Arias-Martinez, J., M. Palacios-Sanchez, D. Delgado-Franco, J. Guzman-Barcenas, E. Garcia-Latorre, L. Zhang and C. Irles. “Clara cell protein expression in human neonates during respiratory distress syndrome.” Cell Physiol Biochem 29(5-6): 753-760 (Mar. 2012). |
| Barnes, H. J., L. Nordlund-Moller, M. Nord, J. Gustafsson, J. Lund and M. Gillner. “Structural basis for calcium binding by uteroglobins.” J Mol Biol 256(2): 392-404 (Nov. 1995). |
| Berlett, B. S. and E. R. Stadtman. “Protein oxidation in aging, disease, and oxidative stress.” J Biol Chem 272(33): 20313-20316 (Aug. 1997). |
| Cai, Z. and L. J. Yan. “Protein Oxidative Modifications: Beneficial Roles in Disease and Health.” J Biochem Pharmacol Res 1(1): 15-26 (Mar. 2013). |
| Callebaut, I., A. Poupon, R. Bally, J. P. Demaret, D. Housset, J. Delettre, P. Hossenlopp and J. P. Mornon. “The uteroglobin fold.” Ann N Y Acad Sci 923: 90-112 (Jan. 2000). |
| Chalker, J. M., L. Lercher, N. R. Rose, C. J. Schofield and B. G. Davis. “Conversion of cysteine into dehydroalanine enables access to synthetic histones bearing diverse post-translational modifications.” Angew Chem Int Ed Engl 51(8): 1835-1839 (Sep. 2011). |
| Davies, K. J., M. E. Delsignore and S. W. Lin. “Protein damage and degradation by oxygen radicals. II. Modification of amino acids.” J Biol Chem 262(20): 9902-9907 (Jul. 1987). |
| Folk, J. E. “Mechanism of action of guinea pig liver transglutaminase. VI. Order of substrate addition.” J Biol Chem 244(13): 3707-3713 (Aug. 1967). |
| Guptasarma, P., D. Balasubramanian, S. Matsugo and I. Saito. “Hydroxyl radical mediated damage to proteins, with special reference to the crystallins.” Biochemistry 31(17): 4296-4303 (Jul. 1991). |
| Hard, T., H. J. Barnes, C. Larsson, J. A. Gustafsson and J. Lund. “Solution structure of a mammalian PCB-binding protein in complex with a PCB.” Nat Struct Biol 2(11): 983-989 (Nov. 1995). |
| Hawkins, C. L., D. I. Pattison and M. J. Davies. “Hypochlorite-induced oxidation of amino acids, peptides and proteins.” Amino Acids 25(3-4): 259-274 (Jan. 2003). |
| Hazen, S. L., F. F. Hsu and J. W. Heinecke. “p-Hydroxyphenylacetaldehyde is the major product of L-tyrosine oxidation by activated human phagocytes. A chloride-dependent mechanism for the conversion of free amino acids into reactive aldehydes by myeloperoxidase.” J Biol Chem 271(4): 1861-1867 (Sep. 1995). |
| Henderson, J. P., J. Byun, M. V. Williams, D. M. Mueller, M. L. McCormick and J. W. Heinecke. “Production of brominating intermediates by myeloperoxidase. A transhalogenation pathway for generating mutagenic nucleobases during inflammation.” J Biol Chem 276(11): 7867-7875 (Nov. 2000). |
| Jeon, J. H. and I. G. Kim. “Role of protein modifications mediated by transglutaminase 2 in human viral diseases.” Front Biosci 11: 221-231 (Jan. 2006). |
| Klug, J., H. M. Beier, A. Bernard, B. S. Chilton, T. P. Fleming, R. I. Lehrer, L. Miele, N. Pattabiraman and G. Singh. “Uteroglobin/Clara cell 10-kDa family of proteins: nomenclature committee report.” Ann N Y Acad Sci 923: 348-354 (2000). |
| Lesort, M., J. Tucholski, M. L. Miller and G. V. Johnson. “Tissue transglutaminase: a possible role in neurodegenerative diseases.” Prog Neurobiol 61(5): 439-463 (Aug. 1999). |
| Lindahl, M., K. Irander, C. Tagesson and B. Stahlbom. “Nasal lavage fluid and proteomics as means to identify the effects of the irritating epoxy chemical dimethylbenzylamine.” Biomarkers 9(1): 56-70 (Sep. 2003). |
| Lindahl, M., J. Svartz and C. Tagesson. “Demonstration of different forms of the anti-inflammatory proteins lipocortin-1 and Clara cell protein-16 in human nasal and bronchoalveolar lavage fluids.” Electrophoresis 20(4-5): 881-890 (Sep. 1998). |
| Lorand, L. and R. M. Graham. “Transglutaminases: crosslinking enzymes with pleiotropic functions.” Nat Rev Mol Cell Biol 4(2): 140-156 (Feb. 2003). |
| Madian, A. G. and F. E. Regnier. “Proteomic identification of carbonylated proteins and their oxidation sites.” J Proteome Res 9(8): 3766-3780 (Aug. 2010). |
| Mantile, G., L. Miele, E. Cordella-Miele, G. Singh, S. L. Katyal and A. B. Mukherjee. “Human Clara cell 10-kDa protein is the counterpart of rabbit uteroglobin.” J Biol Chem 268(27): 20343-20351 (Apr. 1993). |
| Mukherjee, A. B., E. Cordella-Miele, T. Kikukawa and L. Miele. “Modulation of cellular response to antigens by uteroglobin and transglutaminase.” Adv Exp Med Biol 231: 135-152 (Jan. 1988). |
| Mukherjee, A. B., G. C. Kundu, G. Mantile-Selvaggi, C. J. Yuan, A. K. Mandal, S. Chattopadhyay, F. Zheng, N. Pattabiraman and Z. Zhang. “Uteroglobin: a novel cytokine?” Cell Mol Life Sci 55(5): 771-787 (Dec. 1998). |
| Mukherjee, A. B., Z. Zhang and B. S. Chilton. “Uteroglobin: a steroid-inducible immunomodulatory protein that founded the Secretoglobin superfamily.” Endocr Rev 28(7): 707-725 (Oct. 2007). |
| Nagy, P., A. J. Kettle and C. C. Winterbourn. “Superoxide-mediated formation of tyrosine hydroperoxides and methionine sulfoxide in peptides through radical addition and intramolecular oxygen transfer.” J Biol Chem 284(22): 14723-14733 (May 2009). |
| Nemes, Z., L. N. Marekov, L. Fesus and P. M. Steinert. “A novel function for transglutaminase 1: attachment of long-chain omega-hydroxyceramides to involucrin by ester bond formation.” Proc Natl Acad Sci U S A 96(15): 8402-8407 (Jul. 1999). |
| Nicolas, E., C. Ferrer, L. Taboada and E. Giralt. “Coupe du roi bisection of proteins. Spontaneous tetramerization of two peptides that span the sequence of the rabbit uteroglobin monomer.” J Am Chem Soc 127(50): 17719-17733 (Jun. 2005). |
| Ottaviano, F. G., D. E. Handy and J. Loscalzo. “Redox regulation in the extracellular environment.” Circ J 72(1): 1-16 (Oct. 2007). |
| Pedruzzi, E., M. Fay, C. Elbim, M. Gaudry and M. A. Gougerot-Pocidalo. “Differentiation of PLB-985 myeloid cells into mature neutrophils, shown by degranulation of terminally differentiated compartments in response to N-formyl peptide and priming of superoxide anion production by granulocyte-macrophage colony-stimulating factor.” Br J Haematol 117(3): 719-726 (Dec. 2001). |
| Peter, W., R. Dunkel, P. F. Stouten, G. Vriend, M. Beato and G. Suske. “Interchain cysteine bridges control entry of progesterone to the central cavity of the uteroglobin dimer.” Protein Eng 5(4): 351-359 (Jan. 1992). |
| Ramsay, P. L., F. J. DeMayo, S. E. Hegemier, M. E. Wearden, C. V. Smith and S. E. Welty. “Clara cell secretory protein oxidation and expression in premature infants who develop bronchopulmonary dysplasia.” Am J Respir Crit Care Med 164(1): 155-161 (Aug. 2000). |
| Shacter, E. “Quantification and significance of protein oxidation in biological samples.” Drug Metab Rev 32(3-4): 307-326 (Jan. 2000). |
| Shao, B., A. Belaaouaj, C. L. Verlinde, X. Fu and J. W. Heinecke. “Methionine sulfoxide and proteolytic cleavage contribute to the inactivation of cathepsin G by hypochlorous acid: an oxidative mechanism for regulation of serine proteinases by myeloperoxidase.” J Biol Chem 280(32): 29311-29321 (Apr. 2005). |
| Stadtman, E. R. and B. S. Berlett. “Fenton chemistry. Amino acid oxidation.” J Biol Chem 266(26): 17201-17211 (Mar. 1991). |
| Stadtman, E. R., J. Moskovitz, B. S. Berlett and R. L. Levine. “Cyclic oxidation and reduction of protein methionine residues is an important antioxidant mechanism.” Mol Cell Biochem 234-235(1-2): 3-9 (Jan. 2002). |
| Thomas, E. L., M. B. Grisham and M. M. Jefferson. “Preparation and characterization of chloramines.” Methods Enzymol 132: 569-585 (Jan. 1986). |
| Tien, M., B. S. Berlett, R. L. Levine, P. B. Chock and E. R. Stadtman. “Peroxynitrite-mediated modification of proteins at physiological carbon dioxide concentration: pH dependence of carbonyl formation, tyrosine nitration, and methionine oxidation.” Proc Natl Acad Sci U S A 96(14): 7809-7814 (May 1999). |
| Umland, T. C., S. Swaminathan, W. Furey, G. Singh, J. Pletcher and M. Sax. “Refined structure of rat Clara cell 17 kDa protein at 3.0 A resolution.” J Mol Biol 224(2): 441-448 (Nov. 1991). |
| Umland, T. C., S. Swaminathan, G. Singh, V. Warty, W. Furey, J. Pletcher and M. Sax. “Structure of a human Clara cell phospholipid-binding protein-ligand complex at 1.9 A resolution.” Nat Struct Biol 1(8): 538-545 (Aug. 1994). |
| Van Dalen, C. J., C. C. Winterbourn, R. Senthilmohan and A. J. Kettle. “Nitrite as a substrate and inhibitor of myeloperoxidase. Implications for nitration and hypochlorous acid production at sites of inflammation.” J Biol Chem 275(16): 11638-11644 (Dec. 1999). |
| Winterbourn, C. C., M. B. Hampton, J. H. Livesey and A. J. Kettle. “Modeling the reactions of superoxide and myeloperoxidase in the neutrophil phagosome: implications for microbial killing.” J Biol Chem 281(52): 39860-39869 (Jun. 2006). |
| Yan, L. J. and M. J. Forster. “Chemical probes for analysis of carbonylated proteins: a review.” J Chromatogr B Analyt Technol Biomed Life Sci 879(17-18): 1308-1315 (Jan. 2011). |
| Yan, L. J., W. C. Orr and R. S. Sohal. “Identification of oxidized proteins based on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, immunochemical detection, isoelectric focusing, and microsequencing.” Anal Biochem 263(1): 67-71 (Jan. 1998). |
| Yang, C., J. Wang, A. N. Krutchinsky, B. T. Chait, J. D. Morrisett and C. V. Smith. “Selective oxidation in vitro by myeloperoxidase of the N-terminal amine in apolipoprotein B-100.” J Lipid Res 42(11): 1891-1896 (Jan. 2001). |
| Yang, C. Y., Z. W. Gu, M. Yang, S. N. Lin, A. J. Garcia-Prats, L. K. Rogers, S. E. Welty and C. V. Smith. “Selective modification of apoB-100 in the oxidation of low density lipoproteins by myeloperoxidase in vitro.” J Lipid Res 40(4): 686-698 (Feb. 1998). |
| Giannone, “Oxidative modification of recombinant human Clara Cell Secretory Protein (rhCC10) by myeloperoxidase (MPO) and HOCI in vitro.” Pediatric Research 53(4 part 2):416A Annual Meeting of the Pediatric Academic Societies in Seattle, WA USA (May 3-6, 2003). |
| Saavedra, “Influence of chemical modification of amino acid side chains on the binding of progesterone to uteroglobin.” Journal of Steroid Biochemistry 13(11):1347-1353 Nov. 1, 1980. |
| Porta, “Transglutaminase-catalyzed modifications of SV-IV, a major protein secreted from the rat seminal vesicle epithelium.” International Journal of Peptide and Protein Research 35(2):117-122 Feb. 1, 1990. |
| Broeckaert, “Clara Cell secretory protein (cc16): Characteristics and perspectives as lung peripheral biomarker.”, Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 30(4):469-475 (Apr. 1, 2000). |
| Number | Date | Country | |
|---|---|---|---|
| 20210363203 A1 | Nov 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16416268 | May 2019 | US |
| Child | 16896213 | US | |
| Parent | 15212277 | Jul 2016 | US |
| Child | 16416268 | US | |
| Parent | 13843773 | Mar 2013 | US |
| Child | 15212277 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16896213 | Jun 2020 | US |
| Child | 17222531 | US |
